Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma

MLA

Andrew Hsu, et al. “Clinical Activity of 9-ING-41, a Small Molecule Selective Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, in Refractory Adult T-Cell Leukemia/Lymphoma.” Cancer Biology & Therapy, vol. 23, no. 1, Dec. 2022, pp. 417–23. EBSCOhost, https://doi.org/10.1080/15384047.2022.2088984.

APA

Andrew Hsu, Kelsey E. Huntington, Andre De Souza, Lanlan Zhou, Adam J. Olszewski, Nirav P. Makwana, Diana O. Treaba, Ludimila Cavalcante, Francis J. Giles, Howard Safran, Wafik S. El-Deiry, & Benedito A. Carneiro. (2022). Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphoma. Cancer Biology & Therapy, 23(1), 417–423. https://doi.org/10.1080/15384047.2022.2088984

Chicago

Andrew Hsu, Kelsey E. Huntington, Andre De Souza, Lanlan Zhou, Adam J. Olszewski, Nirav P. Makwana, Diana O. Treaba, et al. 2022. “Clinical Activity of 9-ING-41, a Small Molecule Selective Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, in Refractory Adult T-Cell Leukemia/Lymphoma.” Cancer Biology & Therapy 23 (1): 417–23. doi:10.1080/15384047.2022.2088984.